NASDAQ
IRON
Last Price
US $80.01
Valuation
Financial
Performance
Cash flow to debt coverage
Disc Medicine, Inc. cash flow to debt ratio of -9.68K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Free cash flow growth
Disc Medicine, Inc.'s free cash flow has decreased 92.02% from $-94.43M last year to $-181.33M, signaling decreasing performance
Debt-to-equity ratio
Disc Medicine, Inc.'s debt to equity ratio is 0.09, which means that the company's assets are healthy financed, signaling financial stability.
Debt-to-equity trend
Disc Medicine, Inc.'s debt has increased relative to shareholder equity from 0.07 last year to 0.09 today, signaling weakened financials
Net debt to EBITDA
Disc Medicine, Inc. has a net cash position, so leverage is healthy.
Interest coverage
Disc Medicine, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.
Profit margin growth
Disc Medicine, Inc. has insufficient data to evaluate this check.
Current ratio
Disc Medicine, Inc.'s short-term assets of $803.90M exceed its short-term liabilities of $36.64M
Return on assets
Disc Medicine, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Return on equity
Disc Medicine, Inc.'s return on equity of -37.17%, is lower than 15.00%, indicating bad performance
Earnings quality
Disc Medicine, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Earnings stability
Disc Medicine, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings
Positive free cash flow
Disc Medicine, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it
Free cash flow yield
Disc Medicine, Inc. has negative free cash flow, indicating cash burn
Earnings growth
Disc Medicine, Inc.'s yearly earnings has decreased 94.03% since last year from $-109.36M to $-212.18M, signaling decreasing performance
Revenue growth
Disc Medicine, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance
Return on invested capital
ROIC -38.19% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
3-year revenue CAGR
Disc Medicine, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.
Revenue consistency
Disc Medicine, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance
Return on equity consistency
Disc Medicine, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity
Cash Flow Valuation (DCF)
Disc Medicine, Inc. has insufficient data to evaluate this check.
Earnings yield (TTM)
Disc Medicine, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
EBITDA Valuation
Disc Medicine, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
EV/EBITDA (FY)
Disc Medicine, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable
PEG ratio (TTM/FY)
Disc Medicine, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Price-to-book ratio (FY)
Disc Medicine, Inc. has a price-to-book ratio of 4.70x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Price-to-sales ratio (TTM)
Disc Medicine, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue
Profit margin
Current Ratio
Capital Returns
-37.17%
Return on equity
ROIC: -38.19%
Valuation History
-
Price to Earnings
EV/EBITDA: -12.6X
Cash flow
Profit margin
-30.51%
Cash flow
-28.99%
Fair Value
Market $80.01
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.